Veeva Systems (VEEV) AI Stock Analysis

• Market Cap: $48.48B
• Dividend Yield: N/A
• Average Volume (3M): 1.04M
• Price to Earnings (P/E): 61.4
• Beta (1Y): 0.97
• Revenue Growth: 15.33%
• EPS Growth: 30.51%
• Country: US
• Employees: 7,291
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 1.99
• Shares Outstanding: 163,908,020
• 10 Day Avg. Volume: 821,253
• 30 Day Avg. Volume: 1,044,859
• PEG Ratio: 1.52
• Price to Book (P/B): 6.47
• Price to Sales (P/S): 13.75
• P/FCF Ratio: 35.31
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: 13.93
• Enterprise Value/Gross Profit: 18.42
• Enterprise Value/Ebitda: 49.26
• 1Y Price Target: $322.99
• Price Target Upside: 8.77% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 24
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 81 Outperform
• Price Target: $336.00 ▲(13.15% Upside)

Veeva Systems' strong financial performance and positive earnings call are the most significant factors driving the high score. The company's strategic advancements, particularly in AI and the resolution of the IQVIA lawsuit, position it well for future growth. However, the high valuation and some product adoption challenges slightly temper the overall outlook.

Positive Factors

AI Development

The introduction of Veeva AI Agents signifies a strategic move into AI, enhancing product offerings across R&D and quality, potentially transforming industry operations and expanding market reach.

Resolution of IQVIA Lawsuit

Resolving the IQVIA lawsuit removes barriers to data integration, enhancing product capabilities and fostering new collaboration opportunities, which could drive long-term growth.

Strong Balance Sheet

A strong balance sheet with low leverage enhances financial stability and flexibility, allowing Veeva to invest in growth opportunities and weather economic fluctuations.

Negative Factors

Product Adoption Challenges

Challenges in product adoption, such as with Compass Prescriber, could hinder revenue growth and market penetration, impacting long-term strategic goals.

Flat Growth in Commercial Cloud

Flat growth in Commercial Cloud subscriptions may indicate market saturation or competitive pressures, potentially limiting future revenue expansion in this segment.

High Valuation Concerns

A high valuation could limit upside potential and increase vulnerability to market corrections, impacting investor sentiment and capital raising efforts.

Veeva Systems Business Overview & Revenue Model

Company Description

Veeva Systems Inc. is a cloud-based software company that specializes in solutions for the global life sciences industry. Founded in 2007 and headquartered in Pleasanton, California, Veeva provides a suite of applications and services, including customer relationship management (CRM), data management, and regulatory compliance. Its core products, such as Veeva Vault and Veeva CRM, are designed to help pharmaceutical and biotechnology companies streamline operations, enhance collaboration, and ensure compliance with industry regulations.

How the Company Makes Money

Veeva Systems generates revenue primarily through subscription-based services. The company offers its software solutions via a cloud model, allowing customers to pay for access on a recurring basis. Key revenue streams include subscriptions to its various applications, such as Veeva Vault, Veeva CRM, and Veeva Network, which cater to different aspects of life sciences operations, including clinical trials, regulatory submissions, and commercial sales. Veeva also provides professional services to assist clients in implementing and optimizing its software. Significant partnerships with major pharmaceutical companies and ongoing investments in product development further contribute to its earnings, as does the growing demand for cloud-based solutions in the life sciences sector.

Veeva Systems Financial Statement Overview

Summary

Veeva Systems presents a robust financial profile with strong profitability, a solid balance sheet, and impressive cash flow metrics. The company demonstrates consistent revenue growth and efficient operations, supported by low leverage and high equity. Overall, Veeva Systems is well-positioned for continued financial success in the healthcare information services industry.

Income Statement

Veeva Systems demonstrates strong profitability with a TTM gross profit margin of 75.59% and a net profit margin of 27.29%. Revenue growth is steady at 3.95% TTM, indicating consistent expansion. EBIT and EBITDA margins are robust at 29.27% and 29.94% respectively, reflecting efficient operations. Overall, the company shows solid financial health with a positive growth trajectory.

Balance Sheet

The balance sheet is strong with a low debt-to-equity ratio of 0.0129, indicating minimal leverage and financial risk. Return on equity is healthy at 13.40% TTM, showcasing effective use of equity capital. The equity ratio is solid, reflecting a stable financial structure. Veeva Systems maintains a strong balance sheet with low debt and high equity.

Cash Flow

Cash flow metrics are impressive with a free cash flow growth rate of 12.48% TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 1.08, and the free cash flow to net income ratio is 0.99, both suggesting efficient cash flow management. Veeva Systems exhibits strong cash flow performance, supporting its operational and financial stability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.97B	2.75B	2.36B	2.16B	1.85B	1.47B
Gross Profit	2.24B	2.05B	1.69B	1.55B	1.35B	1.06B
EBITDA	839.23M	730.82M	461.96M	488.21M	532.94M	407.25M
Net Income	809.93M	714.14M	525.71M	487.71M	427.39M	380.00M
Balance Sheet
Total Assets	8.00B	7.34B	5.91B	4.80B	3.82B	3.05B
Cash, Cash Equivalents and Short-Term Investments	6.40B	5.15B	4.03B	3.10B	2.38B	1.66B
Total Debt	85.45M	75.78M	55.77M	60.98M	54.59M	63.12M
Total Liabilities	1.36B	1.51B	1.27B	1.09B	904.83M	779.75M
Stockholders Equity	6.64B	5.83B	4.64B	3.72B	2.91B	2.27B
Cash Flow
Free Cash Flow	1.33B	1.07B	885.14M	766.96M	750.25M	542.56M
Operating Cash Flow	1.35B	1.09B	911.34M	780.47M	764.46M	551.25M
Investing Cash Flow	-755.30M	-700.14M	-1.08B	-1.01B	-346.15M	-333.63M
Financing Cash Flow	169.84M	26.11M	-16.19M	-19.38M	-4.14M	33.82M

Veeva Systems Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 296.96
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VEEV, the sentiment is Positive. The current price of 296.96 is above the 20-day moving average (MA) of 291.80, above the 50-day MA of 288.00, and above the 200-day MA of 262.36, indicating a bullish trend. The MACD of 2.07 indicates Negative momentum. The RSI at 56.31 is Neutral, neither overbought nor oversold. The STOCH value of 83.48 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VEEV.

Veeva Systems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VEEV	81 Outperform	$48.48B	61.36	13.70%	―	15.33%	30.51%
HQY	77 Outperform	$8.66B	60.84	6.78%	―	15.45%	37.72%
GEHC	74 Outperform	$34.16B	15.50	24.22%	0.19%	3.52%	32.21%
DOCS	70 Outperform	$9.54B	40.65	24.61%	―	20.21%	44.14%
BTSG	67 Neutral	$5.78B	53.47	4.25%	―	17.23%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TEM	49 Neutral	$12.65B	―	-72.61%	―	72.58%	76.81%

Veeva Systems Corporate Events

Veeva Systems’ Earnings Call Highlights Strategic Wins

Veeva Systems Inc. recently held an earnings call that conveyed a generally positive sentiment, underscored by strong financial performance and strategic advancements. The company highlighted significant progress, particularly with the resolution of the IQVIA lawsuit and advancements in AI development. While challenges such as resistance to certain products and flat growth in one segment were noted, the overall outlook remains optimistic due to these positive developments and future potential.

Veeva Systems Reports Strong Q2 Earnings Growth

Veeva Systems Inc., a prominent provider of cloud-based solutions for the life sciences industry, has reported its fiscal 2026 second-quarter earnings, showcasing significant growth in revenue and profitability.

Veeva Systems and IQVIA Settle Litigation, Announce Partnership

On August 13, 2025, Veeva Systems Inc. and IQVIA Inc. resolved all ongoing litigations that began in 2017 through a settlement agreement, which includes no damages paid by either party. The agreement also facilitates mutual access to data and software, enhancing service offerings for mutual customers. Additionally, Veeva and IQVIA announced global clinical and commercial partnerships aimed at improving efficiency and effectiveness for customers by integrating their software, data, and technology solutions. This collaboration is expected to accelerate clinical development and improve market access for treatments, benefiting shared clients and the overall industry.

The most recent analyst rating on (VEEV) stock is a Buy with a $240.00 price target. To see the full list of analyst forecasts on Veeva Systems stock, see the VEEV Stock Forecast page.